DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

Information source: Amgen
ClinicalTrials.gov processed this data on November 27, 2014
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Psoriasis

Intervention: etanercept (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Amgen

Official(s) and/or principal investigator(s):
MD, Study Director, Affiliation: Amgen

Overall contact:
Amgen Call Center, Phone: 866-572-6436

Summary

This study will evaluate the efficacy of etanercept in plaque psoriasis subjects who have lost a satisfactory response to adalimumab.

Clinical Details

Official title: Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Efficacy of etanercept

Secondary outcome:

Safety of etanercept

Evaluate and compare efficacy and safety in subjects with and without antibodies to adalimumab

Effect of treatment with etanercept on patient reported outcomes

Effect of treatment with etanercept on patient reported outcomes

Effect of treatment with etanercept on patient reported outcomes

Effect of treatment with etanercept on patient reported outcomes

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Moderate to severe plaque psoriasis

- Loss of satisfactory response to adalimumab

- Currently receiving or recently discontinued treatment with adalimumab

Exclusion Criteria:

- Active skin conditions that would interfere with evaluations of the effect of

investigational product on psoriasis

- Serious medical conditions

Locations and Contacts

Amgen Call Center, Phone: 866-572-6436

Research Site, Birmingham, Alabama 35205, United States; Recruiting

Research Site, Mobile, Alabama 36609, United States; Recruiting

Research Site, Phoenix, Arizona 85044, United States; Recruiting

Research Site, Bakersfield, California 93309, United States; Recruiting

Research Site, Encino, California 91436, United States; Recruiting

Research Site, Irvine, California 92697, United States; Recruiting

Research Site, Los Angeles, California 90045, United States; Recruiting

Research Site, Sacramento, California 95816, United States; Recruiting

Research Site, San Francisco, California 94118, United States; Completed

Research Site, San Ramon, California 94583, United States; Completed

Research Site, Santa Monica, California 90404, United States; Recruiting

Research Site, Denver, Colorado 80220, United States; Completed

Research Site, Farmington, Connecticut 06030, United States; Completed

Research Site, Jacksonville, Florida 32204, United States; Completed

Research Site, Miami, Florida 33136, United States; Recruiting

Research Site, St. Petersburg, Florida 33708, United States; Recruiting

Research Site, Tampa, Florida 33609, United States; Recruiting

Research Site, Tampa, Florida 33607, United States; Recruiting

Research Site, Atlanta, Georgia 30342, United States; Recruiting

Research Site, Macon, Georgia 31217, United States; Recruiting

Research Site, Skokie, Illinois 60077, United States; Recruiting

Research Site, New Albany, Indiana 47150, United States; Recruiting

Research Site, Plainfield, Indiana 46168, United States; Completed

Research Site, Louisville, Kentucky 40202, United States; Completed

Research Site, New Orleans, Louisiana 70112, United States; Recruiting

Research Site, Winnipeg, Manitoba R3C 0N2, Canada; Recruiting

Research Site, Boston, Massachusetts 02115, United States; Recruiting

Research Site, St. Louis, Missouri 63117, United States; Recruiting

Research Site, Omaha, Nebraska 68144, United States; Recruiting

Research Site, East Windsor, New Jersey 08520, United States; Recruiting

Research Site, Verona, New Jersey 07044, United States; Recruiting

Research Site, Rochester, New York 14625, United States; Recruiting

Research Site, Halifax, Nova Scotia B3H 0A2, Canada; Recruiting

Research Site, Markham, Ontario L3P 1X2, Canada; Recruiting

Research Site, Peterborough, Ontario K9J 1Z2, Canada; Completed

Research Site, Waterloo, Ontario N2J 1C4, Canada; Recruiting

Research Site, Pittsburgh, Pennsylvania 15213, United States; Recruiting

Research Site, Plymouth Meeting, Pennsylvania 19462, United States; Completed

Research Site, Johnston, Rhode Island 02919, United States; Recruiting

Research Site, Charleston, South Carolina 29414, United States; Recruiting

Research Site, Bartlett, Tennessee 38134, United States; Completed

Research Site, Knoxville, Tennessee 37917, United States; Recruiting

Research Site, Nashville, Tennessee 37215, United States; Completed

Research Site, Dallas, Texas 75231, United States; Completed

Research Site, Houston, Texas 77004, United States; Recruiting

Research Site, Norfolk, Virginia 23507, United States; Completed

Research Site, Walla Walla, Washington 99362, United States; Completed

Additional Information

AmgenTrials clinical trials website

Starting date: October 2011
Last updated: October 10, 2014

Page last updated: November 27, 2014

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014